"eisai" - Google News

Biopharma bites: Eisai maps growth path through 2028, plus UN embraces vaccines to defeat superbugs - FirstWord Pharma

Mon, 25 May 2026 21:44:13 GMT

Biopharma bites: Eisai maps growth path through 2028, plus UN embraces vaccines to defeat superbugs FirstWord Pharma

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation - Eisai

Tue, 17 Mar 2026 07:00:00 GMT

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation Eisai

Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy - BioSpace

Fri, 08 May 2026 07:00:00 GMT

Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy BioSpace

We’re teaming up with Eisai to help fight cancer - Merck.com

Thu, 12 Mar 2026 20:38:25 GMT

We’re teaming up with Eisai to help fight cancer Merck.com

Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026 - PR Newswire

Wed, 20 May 2026 12:08:00 GMT

Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026 PR Newswire

Eisai, Biogen face delay to subcutaneous Leqembi - pharmaphorum

Fri, 08 May 2026 07:00:00 GMT

Eisai, Biogen face delay to subcutaneous Leqembi pharmaphorum

Eisai Co., Ltd. (ESAIY) Analyst/Investor Day - Slideshow (OTCMKTS:ESAIY) 2026-05-25 - Seeking Alpha

Mon, 25 May 2026 09:02:52 GMT

Eisai Co., Ltd. (ESAIY) Analyst/Investor Day - Slideshow (OTCMKTS:ESAIY) 2026-05-25 Seeking Alpha

Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast - Fierce Pharma

Fri, 15 May 2026 07:00:00 GMT

Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast Fierce Pharma

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 - Biogen

Wed, 03 Dec 2025 08:00:00 GMT

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Biogen

Jefferies Adjusts Eisai's Price Target to 4,000 Yen From 5,000 Yen, Keeps at Hold - marketscreener.com

Thu, 28 May 2026 05:29:16 GMT

Jefferies Adjusts Eisai's Price Target to 4,000 Yen From 5,000 Yen, Keeps at Hold marketscreener.com

Merck-Eisai's kidney cancer drug combo fail to improve survival in late-stage trial - Reuters

Tue, 21 Apr 2026 07:00:00 GMT

Merck-Eisai's kidney cancer drug combo fail to improve survival in late-stage trial Reuters

Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027) - Yahoo Finance

Thu, 14 May 2026 07:00:00 GMT

Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027) Yahoo Finance

Eisai becomes a checkpoint player | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Fri, 06 Feb 2026 08:00:00 GMT

Eisai becomes a checkpoint player | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Have Fun Exploring Sleep with Pokémon! Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokémon Sleep" Collaboration | News ReleaseNews Release：2026 - Eisai

Thu, 12 Mar 2026 07:00:00 GMT

Have Fun Exploring Sleep with Pokémon! Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokémon Sleep" Collaboration | News ReleaseNews Release：2026 Eisai

Eisai says Leqembi on track to top $900M in fiscal 2026 - FirstWord Pharma

Fri, 15 May 2026 14:04:43 GMT

Eisai says Leqembi on track to top $900M in fiscal 2026 FirstWord Pharma

Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting - PR Newswire

Thu, 09 Apr 2026 07:00:00 GMT

Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting PR Newswire

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate - BioSpace

Mon, 04 May 2026 07:00:00 GMT

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate BioSpace

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting - PR Newswire

Tue, 10 Mar 2026 07:00:00 GMT

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting PR Newswire

Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer - BioSpace

Tue, 21 Apr 2026 07:00:00 GMT

Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer BioSpace

EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY - PR Newswire

Thu, 26 Mar 2026 07:00:00 GMT

EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY PR Newswire

Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space - BioSpace

Fri, 05 Dec 2025 08:00:00 GMT

Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space BioSpace

Eisai, Biogen Receive Extended FDA Review for Lecanemab Subcutaneous Starting Dose - BioPharm International

Fri, 08 May 2026 07:00:00 GMT

Eisai, Biogen Receive Extended FDA Review for Lecanemab Subcutaneous Starting Dose BioPharm International

Eisai (TSE:4523) Valuation Check As Recent Momentum Meets Mixed Long Term Returns - Yahoo Finance

Sun, 05 Apr 2026 07:00:00 GMT

Eisai (TSE:4523) Valuation Check As Recent Momentum Meets Mixed Long Term Returns Yahoo Finance

Eisai: 2024 TIME100 Most Influential Companies - Time Magazine

Wed, 07 Jan 2026 17:41:21 GMT

Eisai: 2024 TIME100 Most Influential Companies Time Magazine

How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook - Yahoo Finance

Thu, 21 May 2026 07:00:00 GMT

How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook Yahoo Finance

Pharmalittle: We're reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more - statnews.com

Tue, 21 Apr 2026 07:00:00 GMT

Pharmalittle: We're reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more statnews.com

Assessing Eisai (TSE:4523) Valuation After Mixed Share Price Momentum And LEQEMBI Expectations - Yahoo Finance

Sun, 08 Feb 2026 08:00:00 GMT

Assessing Eisai (TSE:4523) Valuation After Mixed Share Price Momentum And LEQEMBI Expectations Yahoo Finance

Tortugas debuts with $106M and brain drugs from Hansoh, Eisai - BioPharma Dive

Tue, 21 Apr 2026 07:00:00 GMT

Tortugas debuts with $106M and brain drugs from Hansoh, Eisai BioPharma Dive

Eisai chooses Pokémon Sleep app to battle bad sleep habits in awareness campaign - Fierce Pharma

Thu, 12 Mar 2026 07:00:00 GMT

Eisai chooses Pokémon Sleep app to battle bad sleep habits in awareness campaign Fierce Pharma

Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb - Pharmaceutical Technology

Thu, 05 Feb 2026 08:00:00 GMT

Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb Pharmaceutical Technology

Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs - BioSpace

Tue, 21 Apr 2026 07:00:00 GMT

Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs BioSpace

Biogen, Eisai forced to wait as FDA extends review of subcutaneous Leqembi starting dose - FirstWord Pharma

Fri, 08 May 2026 07:54:40 GMT

Biogen, Eisai forced to wait as FDA extends review of subcutaneous Leqembi starting dose FirstWord Pharma

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency - PR Newswire

Thu, 26 Mar 2026 07:00:00 GMT

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency PR Newswire

AD/PD 2026: Eisai highlights benefit of continued Leqembi treatment in early Alzheimer’s - Clinical Trials Arena

Wed, 18 Mar 2026 07:00:00 GMT

AD/PD 2026: Eisai highlights benefit of continued Leqembi treatment in early Alzheimer’s Clinical Trials Arena

MSD and Eisai’s RCC combination regimens fail to meet Phase III trial endpoints - Clinical Trials Arena

Wed, 22 Apr 2026 07:00:00 GMT

MSD and Eisai’s RCC combination regimens fail to meet Phase III trial endpoints Clinical Trials Arena

Eisai: Canada's Drug Agency Recommendation Denies Canadians Safer Insomnia Treatments - Yahoo Finance

Thu, 29 Jan 2026 08:00:00 GMT

Eisai: Canada's Drug Agency Recommendation Denies Canadians Safer Insomnia Treatments Yahoo Finance

Eisai's Challenge of Greater Access to Medicines: Tackling Lymphatic Filariasis (video presentation) - Eisai

Wed, 18 Mar 2026 16:52:02 GMT

Eisai's Challenge of Greater Access to Medicines: Tackling Lymphatic Filariasis (video presentation) Eisai

Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib - Yahoo Finance

Wed, 01 Apr 2026 07:00:00 GMT

Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib Yahoo Finance

Eisai, Alzheon Drill Down on Promising Results in High-Risk Alzheimer’s Subset - BioSpace

Fri, 27 Mar 2026 07:00:00 GMT

Eisai, Alzheon Drill Down on Promising Results in High-Risk Alzheimer’s Subset BioSpace

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal - South China Morning Post

Fri, 06 Feb 2026 08:00:00 GMT

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal South China Morning Post

Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment - BioSpace

Thu, 19 Feb 2026 08:00:00 GMT

Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment BioSpace

Is Eisai Now an Opportunity After Mixed Signals from DCF and Earnings Valuation? - Yahoo Finance

Fri, 05 Dec 2025 08:00:00 GMT

Is Eisai Now an Opportunity After Mixed Signals from DCF and Earnings Valuation? Yahoo Finance

Eisai (TSE:4523) Valuation Check After Recent Share Price Pullback And LEQEMBI Growth Story - Yahoo Finance

Sat, 09 May 2026 07:00:00 GMT

Eisai (TSE:4523) Valuation Check After Recent Share Price Pullback And LEQEMBI Growth Story Yahoo Finance

Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - Reuters

Thu, 05 Feb 2026 08:00:00 GMT

Eisai strikes Japan licensing deal with Shanghai Henlius Biotech Reuters

2025 Eisai R&D Day: Deepening Connections - Massachusetts Biotechnology Council

Tue, 16 Sep 2025 07:00:00 GMT

2025 Eisai R&D Day: Deepening Connections Massachusetts Biotechnology Council

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 - PR Newswire

Mon, 01 Dec 2025 08:00:00 GMT

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 PR Newswire

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC - Eisai

Thu, 31 Jul 2025 07:00:00 GMT

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai

Questions mount for Eisai's Elahere wannabe | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Fri, 10 Oct 2025 07:00:00 GMT

Questions mount for Eisai's Elahere wannabe | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Leqembi starts to deliver for Eisai and Biogen - pharmaphorum

Fri, 06 Feb 2026 08:00:00 GMT

Leqembi starts to deliver for Eisai and Biogen pharmaphorum

BMS snags top neuro researcher from Eisai—Chutes & Ladders - Fierce Biotech

Fri, 23 Jan 2026 08:00:00 GMT

BMS snags top neuro researcher from Eisai—Chutes & Ladders Fierce Biotech

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List - Biogen

Mon, 08 Dec 2025 08:00:00 GMT

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List Biogen

Eisai and Biogen Leqembi Iqlik: The Best Inventions of 2025 - Time Magazine

Thu, 09 Oct 2025 07:00:00 GMT

Eisai and Biogen Leqembi Iqlik: The Best Inventions of 2025 Time Magazine

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - BioSpace

Mon, 12 Jan 2026 08:00:00 GMT

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan BioSpace

A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance

Fri, 16 Jan 2026 08:00:00 GMT

A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal Yahoo Finance

Eisai debuts digital destination for kidney cancer to make navigating a diagnosis easier - Medical Marketing and Media

Fri, 06 Mar 2026 08:00:00 GMT

Eisai debuts digital destination for kidney cancer to make navigating a diagnosis easier Medical Marketing and Media

Japan Grants Orphan Drug Designation to Eisai’s Novel Orexin Agonist for Narcolepsy - Sleep Review

Wed, 18 Feb 2026 08:00:00 GMT

Japan Grants Orphan Drug Designation to Eisai’s Novel Orexin Agonist for Narcolepsy Sleep Review

MSD and Eisai to end Phase III LEAP-012 trial for unresectable HCC - Clinical Trials Arena

Thu, 30 Oct 2025 07:00:00 GMT

MSD and Eisai to end Phase III LEAP-012 trial for unresectable HCC Clinical Trials Arena

Eisai Begins Enrolling Phase 2 Study for Narcolepsy Treatment E2086 - Sleep Review

Mon, 30 Mar 2026 07:00:00 GMT

Eisai Begins Enrolling Phase 2 Study for Narcolepsy Treatment E2086 Sleep Review

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 - PR Newswire

Mon, 08 Sep 2025 07:00:00 GMT

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 PR Newswire

Merck, Eisai scrap ambitions for Keytruda-Lenvima pairing in liver cancer subtype after survival miss - Fierce Pharma

Wed, 29 Oct 2025 07:00:00 GMT

Merck, Eisai scrap ambitions for Keytruda-Lenvima pairing in liver cancer subtype after survival miss Fierce Pharma

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status - Biogen

Tue, 02 Sep 2025 07:00:00 GMT

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status Biogen

Eisai shares long-term data on lecanemab at neurology congress - PharmaTimes

Thu, 13 Nov 2025 08:00:00 GMT

Eisai shares long-term data on lecanemab at neurology congress PharmaTimes

Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Yahoo Finance

Thu, 15 Jan 2026 08:00:00 GMT

Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib Yahoo Finance

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s - PMLiVE

Mon, 26 Jan 2026 08:00:00 GMT

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s PMLiVE

Eisai Secures Exclusive Japan Commercial Rights to Henlius’ Anti-PD-1 Serplulimab - BioPharm International

Thu, 05 Feb 2026 08:00:00 GMT

Eisai Secures Exclusive Japan Commercial Rights to Henlius’ Anti-PD-1 Serplulimab BioPharm International

VCs back Tortugas to advance Eisai, Hansoh neurology compounds: Venture Report - biocentury.com

Thu, 23 Apr 2026 07:00:00 GMT

VCs back Tortugas to advance Eisai, Hansoh neurology compounds: Venture Report biocentury.com

Merck, Eisai discontinue late-stage study for liver cancer therapy - Reuters

Wed, 29 Oct 2025 07:00:00 GMT

Merck, Eisai discontinue late-stage study for liver cancer therapy Reuters

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - Yahoo Finance

Wed, 07 Jan 2026 08:00:00 GMT

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan Yahoo Finance

Eisai points the way to kidney cancer support with Kompass digital hub - Fierce Pharma

Thu, 26 Feb 2026 08:00:00 GMT

Eisai points the way to kidney cancer support with Kompass digital hub Fierce Pharma

MSD, Eisai report setback in first-line kidney cancer trial - pharmaphorum

Tue, 21 Apr 2026 07:00:00 GMT

MSD, Eisai report setback in first-line kidney cancer trial pharmaphorum

Eisai joins with Pokémon for sleep awareness drive - pharmaphorum

Thu, 12 Mar 2026 07:00:00 GMT

Eisai joins with Pokémon for sleep awareness drive pharmaphorum

Merck-Eisai's kidney cancer drug combo meets one endpoint of late-stage study - Reuters

Tue, 28 Oct 2025 07:00:00 GMT

Merck-Eisai's kidney cancer drug combo meets one endpoint of late-stage study Reuters

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term - PMLiVE

Wed, 25 Mar 2026 07:00:00 GMT

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term PMLiVE

Eisai secures FDA green light for Leqembi autoinjector, teeing up at-home maintenance dosing - Fierce Pharma

Fri, 29 Aug 2025 07:00:00 GMT

Eisai secures FDA green light for Leqembi autoinjector, teeing up at-home maintenance dosing Fierce Pharma

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 - PR Newswire

Wed, 03 Sep 2025 07:00:00 GMT

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 PR Newswire

MSD, Eisai abandon combination trial in liver cancer - pharmaphorum

Wed, 29 Oct 2025 07:00:00 GMT

MSD, Eisai abandon combination trial in liver cancer pharmaphorum

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters

Fri, 29 Aug 2025 07:00:00 GMT

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug Reuters

ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Clinical Trials Arena

Mon, 20 Oct 2025 07:00:00 GMT

ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Clinical Trials Arena

Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi - BioSpace

Tue, 02 Sep 2025 07:00:00 GMT

Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi BioSpace

Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market - Clinical Trials Arena

Thu, 31 Jul 2025 07:00:00 GMT

Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market Clinical Trials Arena

Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) - Yahoo Finance

Mon, 26 Jan 2026 08:00:00 GMT

Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) Yahoo Finance

Simmons & Simmons advises Eisai on deal with Nuvation Bio - Simmons & Simmons

Wed, 14 Jan 2026 08:00:00 GMT

Simmons & Simmons advises Eisai on deal with Nuvation Bio Simmons & Simmons

Eisai unveils promising phase 1b data for narcolepsy drug E2086 - PharmaTimes

Mon, 08 Sep 2025 07:00:00 GMT

Eisai unveils promising phase 1b data for narcolepsy drug E2086 PharmaTimes

40 Under 40: Michele Randazzo, Eisai - Medical Marketing and Media

Tue, 20 Jan 2026 08:00:00 GMT

40 Under 40: Michele Randazzo, Eisai Medical Marketing and Media

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - Yahoo Finance

Thu, 27 Nov 2025 08:00:00 GMT

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan Yahoo Finance

Merck & Co and Eisai ‘s Phase III LITESPARK-012 trial disappoints - The Pharma Letter

Tue, 21 Apr 2026 07:00:00 GMT

Merck & Co and Eisai ‘s Phase III LITESPARK-012 trial disappoints The Pharma Letter

Merck & Co., Eisai end liver cancer trial after OS miss - FirstWord Pharma

Wed, 29 Oct 2025 07:00:00 GMT

Merck & Co., Eisai end liver cancer trial after OS miss FirstWord Pharma

Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma - PharmExec.com

Thu, 17 Jul 2025 07:00:00 GMT

Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma PharmExec.com

FDA recommends more monitoring of Alzheimer's patients on Eisai-Biogen's drug Leqembi - Reuters

Fri, 29 Aug 2025 07:00:00 GMT

FDA recommends more monitoring of Alzheimer's patients on Eisai-Biogen's drug Leqembi Reuters

Subcutaneous version of Eisai, Biogen's Alzheimer's drug wins FDA approval - FirstWord Pharma

Fri, 29 Aug 2025 07:00:00 GMT

Subcutaneous version of Eisai, Biogen's Alzheimer's drug wins FDA approval FirstWord Pharma

US regulator approves at-home version of Alzheimer’s drug Leqembi from Eisai and Biogen - Financial Times

Fri, 29 Aug 2025 07:00:00 GMT

US regulator approves at-home version of Alzheimer’s drug Leqembi from Eisai and Biogen Financial Times

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) - Business Wire

Tue, 21 Apr 2026 07:00:00 GMT

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) Business Wire

Eisai Showcases Promising 4-Year Data for Alzheimer Therapy Lecanemab at AAIC 2025 - Neurology Live

Thu, 31 Jul 2025 07:00:00 GMT

Eisai Showcases Promising 4-Year Data for Alzheimer Therapy Lecanemab at AAIC 2025 Neurology Live

BioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s disease - European Biotechnology Magazine

Fri, 06 Feb 2026 08:00:00 GMT

BioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s disease European Biotechnology Magazine

Biogen, Eisai’s Leqembi Slows Alzheimer’s Progression Through 4 Years of Treatment - BioSpace

Wed, 30 Jul 2025 07:00:00 GMT

Biogen, Eisai’s Leqembi Slows Alzheimer’s Progression Through 4 Years of Treatment BioSpace

Eisai and advocacy leaders launch website to help patients and caregivers navigate kidney cancer - PharmaLive

Fri, 27 Feb 2026 08:00:00 GMT

Eisai and advocacy leaders launch website to help patients and caregivers navigate kidney cancer PharmaLive

Eisai Highlights Long-Term Efficacy of Lenvima in Advanced HCC Treatment - PharmExec.com

Wed, 16 Jul 2025 07:00:00 GMT

Eisai Highlights Long-Term Efficacy of Lenvima in Advanced HCC Treatment PharmExec.com

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years - PMLiVE

Tue, 12 Aug 2025 07:00:00 GMT

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years PMLiVE

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment - Investor's Business Daily

Fri, 29 Aug 2025 07:00:00 GMT

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment Investor's Business Daily

Eisai licenses Nuvation lung cancer pill; Alnylam’s stock dips after sales data report - Endpoints News

Mon, 12 Jan 2026 08:00:00 GMT

Eisai licenses Nuvation lung cancer pill; Alnylam’s stock dips after sales data report Endpoints News